secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2026-06-10T21:24:02+00:00
Accession:  0001326110-26-000064
Event type: other_material
Sentiment:  neutral
Materiality: 0.05
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio 2026 annual meeting: all directors re-elected, Deloitte ratified
----------------------------------------------------------------------------

- Nine directors, including Patrick Soon-Shiong, re-elected with average ~730M 'for' votes.
- Ratification of Deloitte & Touche as auditor for FY2026 passed: 882M 'for', 1.7M 'against'.
- Approximately 885M shares (85% of outstanding) represented at the June 9, 2026 meeting.
- Broker non-votes of 151.5M shares occurred on director elections (non-discretionary items).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611026000064/0001326110-26-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611026000064/ibrx-20260609.htm
  HTML page:      https://secwatch.observer/filing/0001326110-26-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer